Conference Correspondent

Immunotherapy with ipilimumab improved progression-free survival (PFS) and prostate-specific antigen response compared with placebo, but improvement in overall survival (OS) failed to reach statistical significance in postdocetaxel metastatic castration-resistant prostate cancer (mCRPC)... Read More ›

Men with prostate cancer are often treated with hormone therapy (androgen deprivation therapy [ADT]), but this treatment can have unpleasant and even harmful side effects, including metabolic abnormalities that lead to diabetes mellitus (DM) and cardiovascular disease (CVD). Read More ›

About 7500 participants from more than 90 countries attended the breast cancer symposium. The following are selected brief highlights from these meetings. Read More ›

The keynote address of the Fourth Annual Conference of the Academy of Oncology Nurse & Patient Navigators (AONN+) was delivered by Linda W. Ferris, PhD. Ferris is vice president, Oncology System Service Line, at Centura Health in Colorado and Kansas, as well as chair of the Commission on Cancer (CoC) Accreditation Committee. Read More ›

The 2013 American Society of Clinical Oncology (ASCO) Annual Meeting brought approximately 30,000 cancer specialists to Chicago, Illinois, from May 31 to June 4, 2013. Read More ›

Panelists at the 2013 Annual Conference of the National Comprehensive Cancer Network (NCCN) view the oncology world as rapidly changing, and the impact of this—for better or for worse—will be felt by healthcare providers, payers, and patients alike. Read More ›

The cherry blossoms were in bloom, and the Washington, DC, Convention Center was a bustling hive of activity during the 38th Annual Congress of the Oncology Nursing Society (ONS), held April 25-28, 2013. Read More ›

Significant distress frequently accompanies the diagnosis and treatment of cancer but is often overlooked and is rarely screened for, according to Jimmie C. Holland, MD, of Memorial Sloan-Kettering Cancer Center, New York. Read More ›

Whereas survivorship should be viewed as another stage in the cancer journey—the same as diagnosis and treatment—concerns related to surviving cancer have been largely neglected. Read More ›

Conversations with terminally ill patients about treatment options for end-of-life care often occur when the patient is in pain, heavily medicated, and quite ill—on average, just 1 month before the patient dies. Read More ›